Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.56 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN4A | P35499 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1690189 | 0.88 | SCN9A (0.61) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL1690183 | 0.85 | SCN9A (0.53) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL16319360 | 0.84 | SCN9A (0.62) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL366707 | 0.84 | SCN9A (0.56) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL1690180 | 0.83 | SCN9A (0.55) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL16175229 | 0.83 | SCN9A (0.55) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL363151 | 0.81 | SCN9A (0.58) | SCN9ASCN5A | |
| SCHEMBL364362 | 0.81 | SCN9A (0.55) | SCN9ASCN5AABCB11CYP2C9SCN1A | |
| SCHEMBL363461 | 0.80 | SCN9A (0.60) | SCN9A | |
| SCHEMBL16175324 | 0.80 | SCN9A (0.54) | SCN9ASCN5AABCB11CYP2C9SCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593432-B1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LTD (GB) | 2014-10-22 | — | — | EP | disclosed |
| US-8592629-B2 | Sulfonamide derivatives as Nav 1.7 inhibitors | PFIZER LIMITED (GB) | 2013-11-26 | — | — | US | disclosed |
| EP-2593432-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | Pfizer Limited (GB) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007861-A1 | N-SULFONYLBENZAMIDE DERIVATIVES USEFUL AS VOLTAGE GATED SODIUM CHANNEL INHIBITORS | PFIZER LIMITED (GB) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010183-A1 | Chemical Compounds | PFIZER LIMITED (GB) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010183-A1 | Chemical Compounds | SCN1A, SCN1B, SCN7A | SCN9A 25/4885SCN5A 4/4885ABCB11 645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.